Revisiting the role of beta-amyloid precursor protein immunoreactivity in the neuropathological diagnosis of hypoglycaemia.

Petteri Oura¹, Roosa Koskela², Paula Katriina Vauhkonen²

¹Department of Forensic Medicine, University of Helsinki, P.O. Box 63, Helsinki, FI-00014, Finland; Forensic Medicine Unit, Finnish Institute for Health and Welfare, P.O. Box 30, Helsinki, FI-00271, Finland. Electronic address: petteri.oura@helsinki.fi.

²Department of Forensic Medicine, University of Helsinki, P.O. Box 63, Helsinki, FI-00014, Finland; Forensic Medicine Unit, Finnish Institute for Health and Welfare, P.O. Box 30, Helsinki, FI-00271, Finland.

PubMed DOI

Abstract

The neuropathological diagnosis of hypoglycaemia has long relied on demonstrating the classical pattern of selective neuronal necrosis in affected brain regions. This approach is heavily limited, as hypoglycaemic injury is often indistinguishable from hypoxia-ischaemia. We demonstrate a distinct pattern of beta-amyloid precursor protein (β-APP) immunoreactivity in hypoglycaemic deaths (n = 6), con…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.